Zenyaku Holdings

Zenyaku Holdings is a private Japanese pharmaceutical group that operates primarily through its core subsidiary, Zenyaku Kogyo. The company maintains a diverse portfolio spanning prescription medicines, over-the-counter (OTC) drugs, and specialized skincare products. In the prescription segment, Zenyaku is best known for its strategic partnership with Chugai Pharmaceutical to market Rituxan (rituximab) in Japan, targeting various oncology and autoimmune indications. Its consumer health division is led by the Aruge brand, which focuses on dermatological health for sensitive skin. Zenyaku operates integrated facilities for research, development, and manufacturing within Japan, emphasizing high-quality production standards. The company continues to expand its therapeutic reach through both internal R&D and international collaborations.